ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Session » Pediatric Rheumatology - Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis

Meeting: 2014 ACR/ARHP Annual Meeting

Abstract Number: 269
Discontinuation of Concomitant Medication for Enthesitis-Related Arthritis during 52 Weeks of Treatment with Adalimumab
Abstract Number: 270
Disease Burden Is Comparable in Children with Enthesitis-Related Arthritis and Polyarticular Juvenile Idiopathic Arthritis
Abstract Number: 271
Predicting Treatment Response to Etanercept in Juvenile Idiopathic Arthritis: Results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study (BSPAR-ETN)
Abstract Number: 272
Factors Associated with Choice of First Biologic Among Children with Juvenile Idiopathic Arthritis: A Combined Analysis from 2 UK Paediatric Biologic Registers
Abstract Number: 273
Long-Term Safety and Effectiveness of Adalimumab in Children with Moderately to Severely Active Polyarticular or Polyarticular-Course Juvenile Idiopathic Arthritis
Abstract Number: 274
Treatment Prescribing Patterns in a Cohort of Patients with Juvenile Idiopathic Arthritis (JIA). Data from the Childhood Arthritis Prospective Study
Abstract Number: 275
Environmental Risk Factors and Development of Juvenile Idiopathic Arthritis
Abstract Number: 276
Growth during Tocilizumab Therapy for Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data from a Phase 3 Clinical Trial
Abstract Number: 277
Nearly 20% of Children ARE NOT Correctly Classified According to Current ILAR Classification in a Printo Dataset of More THAN 12,000 Juvenile Idiopathic Arthritis Patients
Abstract Number: 278
Is It Worth Allowing the Presence of Morning Stiffness in the Definition of Inactive Disease in Juvenile Idiopathic Arthritis?
Abstract Number: 279
Focus on Patient Reported Outcomes in Juvenile Idiopathic Arthritis: There Is Room to Improve Care
Abstract Number: 280
Biologic Treatment of Adult Patients with Juvenile Idiopathic Arthritis Followed in the National Registry
Abstract Number: 281
Retrospective Review of Immobilization Vs. Immediate Resumption of Activity in Patients with Oligoarticular Juvenile Idiopathic Arthritis and Corticosteroid Knee Injections
Abstract Number: 282
Pharmacovigilance in Juvenile Idiopathic Arthritis Patients (PHARMACHILD) Treated with Biologic Agents and/or Methotrexate. Consolidated Baseline Characteristics from Pharmachild and Other National Registries
Abstract Number: 283
Agreement Between Enthesitis Evaluation By Manual Palpation and Dolorimetry in Juvenile Spondyloarthritis
Abstract Number: 284
Single Hub and Access Point for Paediatric Rheumatology in Europe (SHARE)– Evidence Based Recommendations for Diagnosis and Treatment of Juvenile Idiopathic Arthritis
Abstract Number: 285
Drug Safety in Treatment of Juvenile Idiopathic Arthritis (JIA): Biologic Therapy Compared with MTX
Abstract Number: 286
Using the 2011 ACR Recommendations for the Treatment of Juvenile Idiopathic Arthritis (JIA) to Evaluate a Single Centre Treatment Pathway: A Feasibility Study
Abstract Number: 287
Role of Joint Status in Decreased Accelerometer-Assessed Daily Physical Activity in Juvenile Idiopathic Arthritis
Abstract Number: 288
Establishing Clinical Meaning and Defining Important Differences in Patient Reported Outcome Measures of Physical Function, Fatigue and Pain Interference in Juvenile Idiopathic Arthritis
Abstract Number: 289
Patient-Reported Outcomes in Children with Moderately to Severely Active Polyarticular or Polyarticular-Course Juvenile Idiopathic Arthritis Who Are Prescribed and Treated with Adalimumab
Abstract Number: 290
Patterns of Active Joint Involvement in JIA
Abstract Number: 291
Development of a Serious Game Designed for Children with Juvenile Idiopathic Arthritis
Abstract Number: 292
Flares in Children with JIA: Results from the Reacch-out Cohort
Abstract Number: 293
Long Term Functional Outcome and Quality of Life of Patients with Refractory Juvenile Idiopathic Arthritis Treated with Etanercept: Results of the Dutch Arthritis and Biologicals in Children Register
Abstract Number: 294
Long-Term Pharmacokinetics of Body Surface Area-Adjusted Doses of Golimumab Following Repeated Subcutaneous Administrations in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis
Abstract Number: 295
Intra-Articular Corticosteroid Injections in Juvenile Idiopathic Arthritis:   Results from a UK Prospective Collaborative Study
Abstract Number: 296
Countermeasures Against Methotrexate Intolerance in Juvenile Idiopathic Arthritis Instituted By Parents Show No Effect
Abstract Number: 297
S100 Proteins in Oligoarticular Juvenile Idiopathic Arthritis
Abstract Number: 298
Long-Term Impact of Juvenile Idiopathic Arthritis in the Greek adults’ Psychosocial Life
Abstract Number: 299
A Controlled Trial of Intra-Articular Corticosteroids with or without Methotrexate in Oligoarticular Juvenile Idiopathic Arthritis
Abstract Number: 300
Patient-Reported Joint Count in Juvenile Idiopathic Arthritis: The Reliability of a Mannequin Format
Abstract Number: 301
Pregnancies in Females with Juvenile Idiopathic Arthritis (JIA) Who Were Exposed to Biologics and/or Methotrexate – Results from a Biologic Register
Abstract Number: 302
Qualitative Assessment of Important Long-Term Outcomes in Juvenile Idiopathic Arthritis
Abstract Number: 303
Predicting Chronic Pain in Children with Juvenile Idiopathic Arthritis: Results from the Childhood Arthritis Prospective Study
Abstract Number: 304
Juvenile Rheumatoid Arthritis and Future Risk for Cardiovascular Disease; A Multicenter Population-Based Study
Abstract Number: 928
A Multinational Study of the Epidemiology, Treatment and Outcome of Childhood Arthritis: Preliminary Data from 6,940 Patients
Abstract Number: 929
Antibiotic Exposure and the Development of Juvenile Idiopathic Arthritis: A Population-Based Case-Control Study
Abstract Number: 930
An Exploratory Analysis of Predictors of Response from 12-Weeks of Canakinumab Therapy in Patients with Active Systemic Juvenile Idiopathic Arthritis
Abstract Number: 931
Response to Canakinumab Treatment Is Maintained in Systemic Juvenile Idiopathic Arthritis Patients
Abstract Number: 932
MRP8/14 Serum Level As Predictor of Response to Starting and Stopping Anti-TNF Treatment in Non-Systemic Juvenile Idiopathic Arthritis
Abstract Number: 933
A Multi-Center, Double-Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab in Pediatric Patients with Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy: Week 48 Results

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.